Tulane pioneers novel ovarian cancer treatmentJuly 18, 2005The Tulane University Section of Hematology and Medical Oncology is investigating a novel treatment for ovarian cancer by using intravenous Ontak to deplete harmful cells that inhibit the body's natural immune response to fight cancer. Ovarian cancer is the fifth leading cancer killer of women in the United States. "This study will test the hypothesis that Ontak improves tumor immunity by killing regulatory T cells (Tregs) in patients with advanced-stage ovarian cancer," says principal investigator Tyler Curiel, professor of medicine and chief of hematology and medical oncology at Tulane. "When a patient has cancer, some of the immune cells in the body begin to kill the body's tumor-killing immune cells instead of killing the tumor. So it's like friendly fire - soldiers, instead of going out and shooting the enemy, shoot their own soldiers instead." In the journal Nature Medicine, Tulane scientists reported how Tregs impede the body's ability to fight ovarian cancer. The Tulane research team showed that human tumor Treg cells suppress tumor immunity and contribute to growth of tumors. Thus, killing Treg cells may help treat cancer, Curiel says.
The National Cancer Institute awarded a four-year grant of more than $1.2 million for the Tulane team to continue studying how ovarian tumors undermine immunity and continue to grow. The Tulane team hopes this novel treatment approach, using Ontak to deplete Tregs, will prove beneficial not only for ovarian cancer, but also for other cancers in future studies, including breast and lung cancer, Curiel says. Ontak has been approved by the U.S. Food and Drug Administration for the treatment of patients with cutaneous T-cell leukemia/lymphoma. Tulane University | |||||||||||||||||||||
|
Related Ovarian Cancer Current Events and Ovarian Cancer News Articles International study supports new standard of treatment for women with advanced ovarian cancer Results of a phase III, international randomized clinical trial demonstrate a new standard of care for treating advanced ovarian cancer that significantly reduces side-effects and post-operative deaths compared to the previously established treatment course. Stanford blood scanner detects even faint indicators of cancer A team led by Stanford researchers has developed a prototype blood scanner that can find cancer markers in the bloodstream in early stages of the disease, potentially allowing for earlier treatment and dramatically improved chances of survival. Study unmasks how ovarian tumors evade immune system Scientists at Johns Hopkins have determined how the characteristic shedding of fatty substances, or lipids, by ovarian tumors allows the cancer to evade the body's immune system, leaving the disease to spread unchecked Jefferson Department of Surgery announces new pancreas tumor registry Charles J. Yeo, M.D., Samuel D. Gross Professor and Chair, Department of Surgery at Jefferson Medical College of Thomas Jefferson University, announces the establishment of the new Jefferson Pancreas Tumor Registry (JPTR). Disease diagnosis in just 15 minutes Testing for diseases such as cancer and multiple sclerosis could soon be as simple as using a pregnancy testing kit. Bio-imaging mass spectrometry techniques reveal molecular details about complex systems Understanding biology at the systems level is difficult, especially when studying complex specimens like tissue slices or communities of organisms in a biofilm. Scientists must be able to identify, quantify and locate the molecules present in the samples. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells A research team, led by investigators at the Department of Surgery at Jefferson Medical College of Thomas Jefferson University and the Kimmel Cancer Center at Jefferson, has achieved a substantial "kill" of pancreatic cancer cells by using nanoparticles to successfully deliver a deadly diphtheria toxin gene. Promising new treatment option for women with recurrent ovarian cancer Combining the new drug trabectedin with pegylated liposomal doxorubicin provides clinical benefit to women with relapsed ovarian cancer, according to new results presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm. Risk of breast cancer mutations underestimated for Asian women, Stanford study shows Oncologist Allison Kurian, MD, and her colleagues at the Stanford University School of Medicine were perplexed. Computer models designed to identify women who might have dangerous genetic mutations that increase their risk of breast and ovarian cancer worked well for white women. But they seemed to be less reliable for another ethnic group. Cryopreservation techniques bring hopes for women cancer victims and endangered species Emerging cryopreservation techniques are increasing hope of restoring fertility for women after diseases such as ovarian cancer that lead to destruction of reproductive tissue. More Ovarian Cancer Current Events and Ovarian Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||